The thyrotropin receptor in thyroid eye disease
- PMID: 9623732
- DOI: 10.1089/thy.1998.8.411
The thyrotropin receptor in thyroid eye disease
Abstract
Thyroid eye disease (TED) has an autoimmune etiology, but the nature of the autoantigen that is the target of the initiating event remains unknown. A number of candidates have been proposed based on Western blotting, library screening, and deduction from sequence similarity. A strong favorite is the thyrotropin receptor (TSHR), which is the target of the thyroid stimulating antibodies (TSAB) of Graves' disease (GD). We have recently demonstrated TSHR transcripts in orbital adipose tissue from a patient with TED by Northern blot, transcripts in normal adipose tissue being at the limit of detection. We have shown that the transcripts are translated into protein by immunohistochemical analysis using two monoclonal antibodies to the TSHR generated by genetic immunization. TSHR immunoreactivity is associated with elongated cells with the appearance of a fibroblast, often adjacent to clusters of adipocytes, in orbital biopsies from patients with TED but not in strabismus or pseudotumor biopsies. In animal studies, we have transferred thyroiditis to naive BALBc and NOD mice, using T cells primed to the human TSHR, either using the receptor expressed as a bacterial fusion protein or by genetic immunization. The BALBc develop a Th2-type response to the receptor, but the NOD a Th1-type with thyrocyte destruction. Orbital pathology, edema, infiltration by mast cells and lymphocytes, and adipose accumulation was also induced in 68% of the BALBc but none of the NOD mice. Together these data indicate that the preadipocyte expresses the TSHR and that a Th2 autoimmune response to the receptor may be an initiating event in TED.
Similar articles
-
Development of an animal model of autoimmune thyroid eye disease.J Immunol. 1999 Apr 15;162(8):4966-74. J Immunol. 1999. PMID: 10202044
-
Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy.J Clin Endocrinol Metab. 1998 Mar;83(3):998-1002. doi: 10.1210/jcem.83.3.4676. J Clin Endocrinol Metab. 1998. PMID: 9506762
-
[Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].Endokrynol Pol. 2011;62 Suppl 1:1-7. Endokrynol Pol. 2011. PMID: 22125104 Review. Polish.
-
Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves' ophthalmopathy.Thyroid. 2001 Oct;11(10):929-34. doi: 10.1089/105072501753210984. Thyroid. 2001. PMID: 11716039
-
Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases?Endokrynol Pol. 2010 Mar-Apr;61(2):222-7. Endokrynol Pol. 2010. PMID: 20464711 Review.
Cited by
-
Epidemiological Status of Thyroid Eye Disease in Central Iran.J Curr Ophthalmol. 2022 Apr 16;34(1):106-111. doi: 10.4103/joco.joco_223_21. eCollection 2022 Jan-Mar. J Curr Ophthalmol. 2022. PMID: 35620368 Free PMC article.
-
Eye muscle antibodies in Graves' ophthalmopathy: pathogenic or secondary epiphenomenon?J Endocrinol Invest. 2004 Mar;27(3):221-9. doi: 10.1007/BF03345270. J Endocrinol Invest. 2004. PMID: 15164997 Review.
-
T cells and fibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy.Br J Ophthalmol. 2000 May;84(5):517-22. doi: 10.1136/bjo.84.5.517. Br J Ophthalmol. 2000. PMID: 10781517 Free PMC article.
-
Genetic immunization of outbred mice with thyrotropin receptor cDNA provides a model of Graves' disease.J Clin Invest. 2000 Mar;105(6):803-11. doi: 10.1172/JCI7665. J Clin Invest. 2000. PMID: 10727449 Free PMC article.
-
New insights into the pathogenesis and nonsurgical management of Graves orbitopathy.Nat Rev Endocrinol. 2020 Feb;16(2):104-116. doi: 10.1038/s41574-019-0305-4. Epub 2019 Dec 30. Nat Rev Endocrinol. 2020. PMID: 31889140 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources